Dazparda
Insulin aspart biosimilar developed by Gan & Lee Pharmaceuticals. Reference product NovoRapid (NovoLog in the United States).
Brands by market: Dazparda (EU) · Commercial partner or holder: Gan & Lee Pharmaceuticals Europe
FDAnot listed
EMAApr 2026authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Dazparda
European Medicines Agency and European CommissionApprovedBrand
Dazparda
Holder or applicant
Gan & Lee Pharmaceuticals Europe GmbH
Pathway
Centralised (Article 10(4))
Approved
Apr 2026
Application or permission
EMEA/H/C/006187
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAApr 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning insulin aspart biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.